News

Results following 12 weeks of treatment confirmed findings from a previous study in not showing a statistically significant benefit of Phenserine treatment over placebo. Patient recruitment for these

The FDA decision is another major blow for Pfizer. At best parecoxib’s path to approval will now be delayed, but the letter could also indicate that the US

The objectives of the study are to determine the response rate and toxicity of Cloretazine in patients with locally advanced or metastatic small-cell lung cancer who have either

ISIS 301012 is a second-generation antisense drug that targets apoB-100, the protein component of low density lipoprotein (LDL, or “bad”) cholesterol. Lowering cholesterol levels is key to the

Berlex’s Zevalin, recently approved in Canada, is indicated for the treatment of adult patients with a certain type of non-Hodgkin’s lymphoma. Zevalin combines the targeting ability of an

In the phase I trial, approximately 70 healthy volunteers will be randomized to receive orally-administered CRA-028129 or placebo. The dose amount and number of days of dosing will

The drug is currently in phase III clinical trials as a treatment for peritumoral edema, or swelling associated with brain tumors. Neurobiological Technologies (NTI) is also eligible to

The trial will evaluate StaphVAX in end-stage renal disease patients on dialysis who are at high risk of contracting S aureus infection during their invasive and long-term treatment.

The molecule studied, known as rEV131 is a recombinant version of a naturally occurring molecule identified in ticks, parasites whose saliva contains immuno-suppressive and immuno-modulatory molecules. The trial